
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna is projected to see substantial product sales growth, with revenues expected to increase from $1.73 billion in 2025 to $2.15 billion in 2026. The company is enhancing its financial position through a $1.5 billion debt deal which strengthens its balance sheet and provides flexibility to navigate uncertainties and capitalize on future opportunities. Additionally, improvements in manufacturing efficiency are anticipated to restore gross margins from a low of 30% in 2023 to around 50% by 2025, further underpinning the company's profitability outlook.
Bears say
Moderna's stock outlook is negatively impacted by a significant decline in COVID vaccine sales, which dropped from $18 billion in 2022 to $6.7 billion in 2023, coupled with reduced revenue guidance due to waning vaccination rates and increased competition from other RSV vaccines. Additionally, the company's overall revenue growth potential appears limited, as evidenced by the decreased valuation of its COVID-related products from $11.70 billion to $10.50 billion, reflecting an ongoing transition from pandemic to endemic conditions. Furthermore, issues such as low expectations for EU sales negotiations and slow progress in their clinical pipeline outside of respiratory vaccines contribute to the prevailing uncertainties surrounding Moderna's financial future.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares